Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update

Arbutus Biopharma Co. (NASDAQ:ABUS) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 6,060,000 shares, a decrease of 7.3% from the October 31st total of 6,540,000 shares. Based on an average daily volume of 1,150,000 shares, the short-interest ratio is presently 5.3 days.

Institutional Investors Weigh In On Arbutus Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in Arbutus Biopharma during the 2nd quarter valued at approximately $34,000. Helen Stephens Group LLC acquired a new position in shares of Arbutus Biopharma during the third quarter worth approximately $50,000. Walleye Trading LLC bought a new stake in shares of Arbutus Biopharma in the first quarter valued at approximately $36,000. XTX Topco Ltd acquired a new stake in shares of Arbutus Biopharma in the second quarter worth $53,000. Finally, Premier Path Wealth Partners LLC increased its position in Arbutus Biopharma by 18.0% during the second quarter. Premier Path Wealth Partners LLC now owns 36,000 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 5,500 shares during the period. 43.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $5.00 price target (up from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. Jefferies Financial Group boosted their target price on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Monday, November 18th. Finally, JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Trading Down 0.3 %

Shares of Arbutus Biopharma stock opened at $3.46 on Monday. The stock has a market capitalization of $655.64 million, a price-to-earnings ratio of -8.05 and a beta of 1.92. Arbutus Biopharma has a 1-year low of $1.92 and a 1-year high of $4.72. The firm has a fifty day simple moving average of $3.81 and a 200-day simple moving average of $3.67.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.